Involvement of IL17A, IL17F and IL23R polymorphisms in colorectal cancer therapy

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Omrane, Inés ^a   Medimegh, Imen ^a   Baroudi, Olfa ^a   Ayari, Hager ^a   Bedhiafi, Walid ^a   Stambouli, Nejla ^a   Ferchichi, Marwa ^a   Kourda, Nadia ^b   Bignon, Yves Jean ^c   Uhrhammer, Nancy ^c   Mezlini, Amel ^d   Bougatef, Karim ^a   Benammar Elgaaied, Amel ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

^c CENTRE JEAN PERRIN   (France)

^d SALAH AZAIEZ INSTITUTE   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 23 RECEPTOR; IL17A PROTEIN, HUMAN; IL17F PROTEIN, HUMAN; IL23R PROTEIN, HUMAN; INTERLEUKIN RECEPTOR;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IL17A GENE; IL17F GENE; IL23R GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TUNISIA; TUNISIAN; WILD TYPE; AGED; COLORECTAL NEOPLASMS; GAMMA RADIATION; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; SURVIVAL ANALYSIS; THERAPEUTIC USE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; GAMMA RAYS; GENE EXPRESSION; GENOTYPE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN; SURVIVAL ANALYSIS;

EID: 84939209351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128911     Document Type: Article

References (53)

1. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature immunology. 2005;6(11):1123-32. PMID: 16200070.
2. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol. 2009;183(7):4169-75. PMID: 19767566. doi: 10.4049/jimmunol.0901017
3. Mumm JB, Oft M. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene. 2008;27(45):5913-9. PMID: 18836472. doi: 10.1038/onc.2008.275
4. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent proand antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. The Journal of experimental medicine. 2003;198(12):1951-7. PMID: 14662908.
5. Zhang X, Yu P, Wang Y, Jiang W, Shen F, Wang Y, et al. Genetic polymorphisms of interleukin 17A and interleukin 17F and their association with inflammatory bowel disease in a Chinese Han population. Inflamm Res. 2013;62(8):743-50. PMID: 23652560. doi: 10.1007/s00011-013-0629-9
6. Yu P, Shen F, Zhang X, Cao R, Zhao X, Liu P, et al. Association of single nucleotide polymorphisms of IL23R and IL17 with ulcerative colitis risk in a Chinese Han population. PloS one. 2012;7(9):e44380. PMID: 22984500. doi: 10.1371/journal.pone.0044380
7. Chen J, Deng Y, Zhao J, Luo Z, Peng W, Yang J, et al. The polymorphism of IL-17 G-152A was associated with childhood asthma and bacterial colonization of the hypopharynx in bronchiolitis. Journal of clinical immunology. 2010;30(4):539-45. PMID: 20437253. doi: 10.1007/s10875-010-9391-8
8. He D, Li H, Yusuf N, Elmets CA, Athar M, Katiyar SK, et al. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PloS one. 2012;7(2):e32126. PMID: 22359662. doi: 10. 1371/journal.pone.0032126
9. Wu D, Wu P, Huang Q, Liu Y, Ye J, Huang J. Interleukin-17: a promoter in colorectal cancer progression. Clinical & developmental immunology. 2013;2013:436307. PMID: 24382972.
10. Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, et al. T helper 17 cells play a critical pathogenic role in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(15):5664-9. PMID: 24706787. doi: 10.1073/pnas.1319051111
11. Kryczek I, Wu K, Zhao E, Wei S, Vatan L, Szeliga W, et al. IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol. 2011;186(7):4388-95. PMID: 21357259. doi: 10.4049/jimmunol.1003251
12. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. The Journal of clinical investigation. 2007;117(5):1175-83. PMID: 17476347.
13. McGovern DP, Rotter JI, Mei L, Haritunians T, Landers C, Derkowski C, et al. Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease. Inflammatory bowel diseases. 2009;15(6):883-9. PMID: 19235914. doi: 10.1002/ibd.20855
14. Huber AK, Jacobson EM, Jazdzewski K, Concepcion ES, Tomer Y. Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. The Journal of clinical endocrinology and metabolism. 2008;93(3):1077-81. PMID: 18073300.
15. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178(11):6730-3. PMID: 17513719.
16. Suzuki H, Ogawa H, Miura K, Haneda S, Watanabe K, Ohnuma S, et al. IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma. Oncology letters. 2012;4(2):199-204. PMID: 22844353.
17. Chen J, Lu Y, Zhang H, Ding Y, Ren C, Hua Z, et al. A nonsynonymous polymorphism in IL23R gene is associated with risk of gastric cancer in a Chinese population. Molecular carcinogenesis. 2010;49(10):862-8. PMID: 20607725. doi: 10.1002/mc.20661
18. Zhou B, Zhang P, Wang Y, Shi S, Zhang K, Liao H, et al. Interleukin-17 gene polymorphisms are associated with bladder cancer in a chinese han population. Molecular carcinogenesis. 2012;52(11):871-8. PMID: 22692973. doi: 10.1002/mc.21928
19. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, et al. Effect of polymorphisms of IL-17A, -17F and MIF genes on CpG island hyper-methylation (CIHM) in the human gastric mucosa. International journal of molecular medicine. 2009;24(4):563-9. PMID: 19724898.
20. Zheng J, Jiang L, Zhang L, Yang L, Deng J, You Y, et al. Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations. Carcinogenesis. 2012;33(12):2409-16. PMID: 23042301. doi: 10.1093/carcin/bgs307
21. Omrane I, Baroudi O, Bougatef K, Mezlini A, Abidi A, Medimegh I, et al. Significant association between IL23R and IL17F polymorphisms and clinical features of colorectal cancer. Immunology letters. 2014;158(1-2):189-94. PMID: 24440568. doi: 10.1016/j.imlet.2014.01.005
22. Omrane I, Marrakchi R, Baroudi O, Mezlini A, Ayari H, Medimegh I, et al. Significant association between interleukin-17A polymorphism and colorectal cancer. Tumour Biol. 2014;35(7):6627-32. PMID: 24699997. doi: 10.1007/s13277-014-1890-4
23. Omrane I, Mezlini A, Baroudi O, Stambouli N, Bougatef K, Ayari H, et al. 3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer. Medical oncology (Northwood, London, England). 2014;31(5):954. PMID: 24719038. doi: 10.1007/s12032-014-0954-z
24. Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, et al. A protective role by interleukin-17F in colon tumorigenesis. PloS one. 2012;7(4):e34959. PMID: 22509371. doi: 10.1371/journal.pone.0034959
25. Slattery ML, Wolff RK, Herrick JS, Caan BJ, Potter JD. IL6 genotypes and colon and rectal cancer. Cancer Causes Control. 2007;18(10):1095-105. PMID: 17694420.
26. Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer research. 2006;26(5 B):3905-11. PMID: 17094421.
27. Hsu CP, Chung YC. Influence of interleukin-6 on the invasiveness of human colorectal carcinoma. Anticancer research. 2006;26(6 B):4607-14. PMID: 17201185.
28. Wilkening S, Tavelin B, Canzian F, Enquist K, Palmqvist R, Altieri A, et al. Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis. 2008;29(6):1202-6. PMID: 18448485. doi: 10.1093/carcin/bgn101
29. de Jong KP, Slooff MJ. [Resection of liver metastasis: higher chance of survival]. Nederlands tijdschrift voor geneeskunde. 2002;146(5):196-9. PMID: 11851077.
30. Gallagher G, Lindemann M, Oh HH, Ferencik S, Walz MK, Schmitz A, et al. Association of the TNFa2 microsatellite allele with the presence of colorectal cancer. Tissue antigens. 1997;50(1):47-51. PMID: 9243755.
31. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620-7. PMID: 12411307.
32. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. The Journal of allergy and clinical immunology. 2004;114(6):1265-73; quiz 74. PMID: 15577820.
33. Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Annals of surgery. 2005;242(5):693-700. PMID: 16244543.
34. Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, et al. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Alimentary pharmacology & therapeutics. 2004;19(10):1073-8. PMID: 15142196.
35. Laghi L, Costa S, Saibeni S, Bianchi P, Omodei P, Carrara A, et al. Carriage of CARD15 variants and smoking as risk factors for resective surgery in patients with Crohn's ileal disease. Alimentary pharmacology & therapeutics. 2005;22(6):557-64. PMID: 16167972.
36. Russell RK, Drummond HE, Nimmo EE, Anderson N, Smith L, Wilson DC, et al. Genotype-phenotype analysis in childhood-onset Crohn's disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflammatory bowel diseases. 2005;11(11):955-64. PMID: 16239840.
37. Barreiro M, Nunez C, Dominguez-Munoz JE, Lorenzo A, Barreiro F, Potel J, et al. Association of NOD2/CARD15 mutations with previous surgical procedures in Crohn's disease. Rev Esp Enferm Dig. 2005;97(8):547-53. PMID: 16266221.
38. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer research. 2008;68(11):4026-30. PMID: 18519658. doi: 10.1158/0008-5472. CAN-08-0427
39. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. The Journal of experimental medicine. 2005;202(12):1691-701. PMID: 16365148.
40. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature medicine. 2007;13(9):1050-9. PMID: 17704786.
41. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer research. 2009;69(13):5383-91. PMID: 19549917. doi: 10.1158/0008-5472. CAN-08-3845
42. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nature medicine. 2009;15(10):1170-8. PMID: 19767732. doi: 10.1038/nm.2028
43. Wedebye Schmidt EG, Larsen HL, Kristensen NN, Poulsen SS, Lynge Pedersen AM, Claesson MH, et al. TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflammatory bowel diseases. 2013;19(8):1567-76. PMID: 23689808. doi: 10.1097/MIB.0b013e318286fa1c
44. McLean LP, Cross RK, Shea-Donohue T. Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis. Immunotherapy. 2013;5(9):923-5. PMID: 23998727. doi: 10. 2217/imt.13.87
45. Reppert S, Boross I, Koslowski M, Tureci O, Koch S, Lehr HA, et al. A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nature communications. 2011;2:600. PMID: 22186896. doi: 10.1038/ncomms1609
46. Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Scientific reports. 2013;3:3456. PMID: 24316750. doi: 10.1038/srep03456
47. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. Jama. 2009;302(13):1429-36. PMID: 19809024. doi: 10.1001/jama.2009.1420
48. Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2007;56(2):281-8. PMID: 17222938.
49. Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO, Lothe RA. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol. 2003;21(5):820-9. PMID: 12610180.
50. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung cancer (Amsterdam, Netherlands). 2013;69(3):348-54. PMID: 20022135.
51. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. Journal of hepatology. 2009;50(5):980-9. PMID: 19329213. doi: 10.1016/j.jhep. 2008.12.033
52. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochemical and biophysical research communications. 2011;407(2):348-54. PMID: 21396350. doi: 10.1016/j. bbrc.2011.03.021
53. Hitre E, Budai B, Adleff V, Czegledi F, Horvath Z, Gyergyay F, et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenetics and genomics. 2005;15(10):723-30. PMID: 16141798.